Williams R R, Rao D C, Ellison R C, Arnett D K, Heiss G, Oberman A, Eckfeldt J H, Leppert M F, Province M A, Mockrin S C, Hunt S C
Cardiovascular Genetics Research Clinic, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Ann Epidemiol. 2000 Aug;10(6):389-400. doi: 10.1016/s1047-2797(00)00063-6.
Hypertension is a common precursor of serious disorders including stroke, myocardial infarction, congestive heart failure, and renal failure in whites and to a greater extent in African Americans. Large genetic-epidemiological studies of hypertension are needed to gain information that will improve future methods for diagnosis, treatment, and prevention of hypertension, a major contributor to cardiovascular morbidity and mortality.
We report successful implementation of a new structure of research collaboration involving four NHLBI "Networks," coordinated under the Family Blood Pressure Program. The Hypertension Genetic Epidemiology Network (HyperGEN) involves scientists from six universities and the NHLBI who seek to identify and characterize genes promoting hypertension. Blood samples and clinical data were projected to be collected from a sample of 2244 hypertensive siblings diagnosed before age 60 from 960 sibships (half African-American) with two or more affected persons. Nonparametric sibship linkage analysis of over one million genotype determinations (20 candidate loci and 387 anonymous marker loci) was projected to have sufficient power for detecting genetic loci promoting hypertension. For loci showing evidence for linkage in this study and for loci reported linked or associated with hypertension by other groups, genotypes are compared in hypertensive cases versus population-based controls to identify or confirm genetic variants associated with hypertension. For some of these genetic variants associated with hypertension, detailed physiological and biochemical characterization of untreated adult offspring carriers versus non-carriers may help elucidate the pathophysiological mechanisms that promote hypertension.
The projected sample size of 2244 hypertensive participants was surpassed, as 2407 hypertensive individuals (1262 African-Americans and 1145 whites) from 917 sibships were examined. Detailed consent forms were designed to offer participants several options for DNA testing; 94% of participants gave permission for DNA testing now or in the future for any confidential medical research, with only 6% requesting restrictions for tests performed on their DNA. Since this is a family study, participants also are asked to list all first degree relatives (along with names, addresses, and phone numbers) and to indicate for each relative whether they were willing to allow study staff to make a contact. Seventy percent gave permission to contact some relatives; about 30% gave permission to contact all first degree relatives; and less than 1% asked that no relatives be contacted. Successes after the first four years of this study include: 1) productive collaboration of eight centers from six different locations; 2) early achievement of recruitment goals for study participants including African-Americans; 3) an encouraging rate of consent for DNA testing (including future testing) and relative contacting; 4) completed analyses of genetic linkage and association for several candidate gene markers and polymorphisms; 5) completed genotyping of random markers for over half of the full sample; and 6) early sharing of results among the four Family Blood Pressure Program networks for candidate and genome search analyses.
Experience after four years of this five-year program (1995-2000) suggests that the newly initiated NHLBI Network Program mechanism is fulfilling many of the expectations for which it was designed. It may serve as a paradigm for future genetic research that can benefit from large sample sizes, frequent sharing of ideas among laboratories, and prompt independent confirmation of early findings, which are required in the search for common genes with relatively small effects such as those that predispose to human hypertension.
高血压是包括中风、心肌梗死、充血性心力衰竭和肾衰竭等严重疾病的常见先兆,在白人中如此,在非裔美国人中更为常见。需要开展大规模的高血压遗传流行病学研究,以获取能改进未来高血压诊断、治疗和预防方法的信息,高血压是心血管疾病发病率和死亡率的主要促成因素。
我们报告了一项新的研究合作结构的成功实施,该结构涉及四个美国国立心肺血液研究所(NHLBI)的“网络”,由家庭血压项目进行协调。高血压遗传流行病学网络(HyperGEN)由来自六所大学的科学家和NHLBI的人员组成,他们试图识别和描述导致高血压的基因。计划从960个同胞手足(其中一半是非裔美国人)中选取2244名60岁前被诊断为高血压的同胞手足作为样本,收集他们的血样和临床数据,每个同胞手足中有两个或更多患病者。对超过一百万个基因型测定(20个候选基因座和387个匿名标记基因座)进行非参数同胞手足连锁分析,预计有足够的效力来检测导致高血压的基因座。对于在本研究中显示出连锁证据的基因座以及其他研究小组报告的与高血压连锁或相关的基因座,将在高血压病例与基于人群的对照中比较基因型,以识别或确认与高血压相关的基因变异。对于其中一些与高血压相关的基因变异,对未经治疗的成年后代携带者与非携带者进行详细的生理和生化特征分析,可能有助于阐明导致高血压的病理生理机制。
实际检测了来自917个同胞手足的2407名高血压个体(1262名非裔美国人和1145名白人),超过了计划的2244名高血压参与者的样本量。设计了详细的知情同意书,为参与者提供多种DNA检测选项;94%的参与者允许现在或将来为任何保密医学研究进行DNA检测,只有6%的人要求对其DNA检测加以限制。由于这是一项家族研究,还要求参与者列出所有一级亲属(包括姓名、地址和电话号码),并指明每个亲属是否愿意让研究人员与其联系。70%的人允许联系一些亲属;约30%的人允许联系所有一级亲属;不到1%的人要求不联系任何亲属。这项研究头四年取得的成果包括:1)来自六个不同地点的八个中心开展了富有成效的合作;2)包括非裔美国人在内的研究参与者招募目标提前实现;3)DNA检测(包括未来检测)和亲属联系的同意率令人鼓舞;4)完成了对几个候选基因标记和多态性的遗传连锁和关联分析;5)完成了超过一半完整样本的随机标记基因分型;6)在四个家庭血压项目网络之间提前分享了候选基因和基因组搜索分析的结果。
这个为期五年的项目(1995 - 2000年)实施四年后的经验表明,新启动的NHLBI网络项目机制正在实现其设计时的许多预期目标。它可能成为未来遗传研究的一个范例,这种研究能够受益于大样本量、实验室之间频繁的思想交流以及对早期发现的及时独立验证,这些对于寻找像那些易导致人类高血压的、效应相对较小的常见基因来说是必需的。